DCM
ZVRA icon

DGS Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

DGS Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$138K Hold
14,810
– – 0.02% 577
2025
Q4 		$133K Buy
+14,810
New +$140K 0.02% 496

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

DGS Capital Management's ZVRA Position: Q1 2026 in Review

DGS Capital Management held its Zevra Therapeutics (ZVRA) position steady in Q1 2026 at 14,810 shares worth $138K. The position accounts for 0.02% of the portfolio, ranked #577.

DGS Capital Management first reported a position in ZVRA in Q4 2025 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • DGS Capital Management held 14,810 shares of Zevra Therapeutics worth $138K as of Q1 2026.
  • DGS Capital Management left its Zevra Therapeutics share count unchanged in Q1 2026.
  • Zevra Therapeutics made up 0.02% of DGS Capital Management's portfolio in Q1 2026, its #577 holding.
  • DGS Capital Management first reported a position in Zevra Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.